Prostate Cancer Screening for Gay Men in the United States

Urology. 2022 May:163:119-125. doi: 10.1016/j.urology.2021.07.027. Epub 2021 Aug 8.

Abstract

Objective: To elucidate trends of prostate-cancer (PCa) screening in gay and bisexual men and assess the association of sexual orientation with PCa screening in the United States of America.

Methods: Data for men ≥40 years-old with no history of PCa were collected from the National Health Interview Survey for the years 2013, 2015, and 2018. Multivariable logistic regression models were created to determine the associations between sexual orientation and PCa screening and the discussion of advantages and disadvantages prior to PCa screening.

Results: Gay men screened for prostate cancer were younger than their straight counterparts with a median age (IQR) of 58 years (52-66) vs 64 years (56-71). Gay men were more likely to have undergone a screening PSA test (OR 1.56; 95% CI 1.20-2.02) and discuss the advantages of PSA testing with the physician prior to the test (OR 1.64; 95% CI 1.22-2.21) when compared to straight men. In yearly analysis, gay men were more likely to have undergone screening in 2013 (OR 1.65, 95% CI 1.01-2.68) and 2015 (OR 1.95, 95 CI% 1.30-2.91), however, there was no difference when compared to straight men in 2018 (OR 1.32, 95% CI 0.85-2.04).

Conclusion: Gay men were screened for PCa at a younger age comparted to straight men. They were also more likely to have undergone PCa cancer screening than straight men between 2013 and 2018. Further study is needed to better understand the role of sexual orientation in PCa screening and management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bisexuality
  • Early Detection of Cancer* / statistics & numerical data
  • Humans
  • Male
  • Mass Screening / statistics & numerical data
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnosis
  • Sexual and Gender Minorities*
  • United States / epidemiology

Substances

  • Prostate-Specific Antigen